您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > BGP-15
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
BGP-15
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
BGP-15图片
CAS NO:66611-38-9
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)351.27
FormulaC14H24Cl2N4O2
CAS No.66611-37-8
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 11.33 mg/mL
Water: N/A
Ethanol: N/A
Other info

Chemical Name: N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidamide

SMILES Code: N=C(NOCC(O)CN1CCCCC1)C2=CN=CC=C2

Synonyms

BGP15; BGP-15; BGP 15; BGP15 hydrochloride; BGP15 HCl; N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidamide dihydrochloride

实验参考方法
In Vitro

In vitro activity: BGP-15 (200 μM) prevents the imatinib mesylate-induced oxidative damages, attenuates the depletion of high-energy phosphates, alters the signaling effect of imatinib mesylate by preventing p38 MAP kinase and JNK activation, and induced the phosphorylation of Akt and GSK-3beta.


Cell Assay: Previous study showed that BGP-15 at 200 μM could prevent the imatinib-induced oxidative damages, attenuate the depletion of high-energy phosphates, alter the signaling effect of imatinib by preventing p38 MAP kinase and JNK activation, and also induce the Akt and GSK-3β phosphorylation.

In VivoBGP-15 (15 mg/kg, p.o.) does not improve skeletal muscle pathology in older mdx mice. In a rat model, 10 days of BGP-15 treatment greatly improves diaphragm muscle fiber function (by about 100%), although it does not reverse diaphragm atrophy. The treatment also provides protection from myosin PTMs associated with HSP72 induction and PARP-1 inhibition, resulting in improvement of mitochondrial function and content. BGP-15 (15 mg/kg per day in saline) treatment has no effect in Ntg mice or an independent cohort of normal adult wild-type mice based on morphology, cardiac function and ECG parameters. Treatment with BGP-15 attenuates the increase in atrial size and lung weight. BGP-15 treatment is able to prevent or reduce episodes of arrhythmia. BGP-15 treatment is associated with a reduced PR interval in the HF+AF model.
Animal modelMice
Formulation & Dosage15 mg/kg, p.o.
References

Am J Pathol. 2016 Dec;186(12):3246-3260; Sci Transl Med. 2016 Aug 3;8(350):350ra103; Nat Commun. 2014 Dec 9;5:5705.